APASLAsian Pacific Association for the Study of the Liver (Japan)
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Kilavuzlara Gore Kronik Hepatit B'de Antiviral Tedavi Kesilme Onerilerinin Ozeti Kilavuz HBeAg-Pozitif HBeAg-Negatif EASL 2017 (13) HBsAg klirensi (en HBsAg klirensi guvenlisi) Secilmis hastalarda HBeAg [greater than or serokonversiyonu ve equal to] 3 yil HBV DNA'nin tedaviyi virolojik baskilanma takiben 6-12 ay elde edilmisse ve NA saptanamaz halde kesilince en az bir olmasi yil takip guvencesi saglanmissa AASLD 2018 (14) HBsAg klirensi HBsAg klirensi Hasta temelinde degerlendirilmeli, riskler hastaya anlatilmali ve karar hastaya ve hekimine birakilmali APASL 2016 (15) HBeAg Anti-HBs serokonversiyonu serokonversiyonuyla beraberinde birlikte HBsAg tedavinin 1-3.
The health forum, 'Towards Elimination of Viral Hepatitis by 2030: From the Clinic to Community,' was jointly organised by the Asia Pacific Association for the Study of the Liver (APASL), and the Coalition for the Eradication of Viral Hepatitis in Asia Pacific (CEVHAP), working closely with a number of multisectoral organizations, including the Hepatology Association of the Philippines, the Yellow Warrior Society of the Philippines, ZeShan Foundation, the World Hepatitis Alliance and the WHO.
International societies' HCC screening guidelines AASLD guidelines EASL guidelines [4] APASL guidelines[52] [40, 51] Screen the following Screen the following Screen the following groups (moderate groups (moderate/ groups (moderate evidence): high evidence): evidence): 1.
Recent guidelines for the management of HBV were published by WHO, AASLD, and APASL in 2015 and by EASL in 2017 (1-4).
In the clinical guideline of 2015 AASLD, APASL, 2015 guidelines for the prevention and treatment of CHB in China, 2017 EASL, the adopted direct parameters for active liver inflammation were ALT and HBV DNA.
Study entry criteria were as follows: (1) age 18 years or above; (2) diagnosis of HBV carrier, chronic hepatitis B (CHB), hepatitis B cirrhosis or HBV-related Hepatocellular Carcinoma (HCC) according to the Guidelines of Prevention and Treatment for Chronic Hepatitis B (2010 version) [21] and the Recommendations of the Asian Pacific Association for the Study of the Liver (APASL) for the management of hepatocellular carcinoma; [22] (3) a total score of 7 or above on the Montgomery-Asberg Depression Rating Scale (MADRS) indicating at least mild depression; [34] (4) ability to communicate, understand the purpose of the study and tolerate a one-hour interview.
The Asia-Pacific Association for the Study of liver (APASL) guideline [23] recommends ALT and HBVDNA levels as indicators of active hepatitis B.
The launching of the 2019 APASL Annual Meeting in Manila Highlights.
Patients were explained response guided therapy plan as suggested in guidelines of Asia Pacific Association for Study of Liver Diseases (APASL).11 Informed consent was obtained on start of study.
Non-cirrhotic portal fibrosis/ idiopathic portal hypertension: APASL recommendations for diagnosis and treatment.
Given the increasing evidence for the efficacy, safety, and economic value of antiviral prophylaxis during pregnancy, in 2012 the European Association for the Study of the Liver (EASL) and the Asian Pacific Association for the Study of the Liver (APASL) recommended considering a prophylactic antiviral in the third trimester for pregnant women with high viral load.